Eli Lilly moves to expand Zepbound access

Advertisement

Eli Lilly is broadening its direct-to-consumer approach by partnering with a digital health company, Noom, which is focused on weight management. 

The collaboration connects Noom users with Eli Lilly’s pharmacy provider, GiftHealth, to facilitate access to Zepbound single-dose vials for individuals with a prescription, according to a March 31 Noom news release. 

The integration also allows users to track prescription fill statuses and shipping dates within an app. Eli Lilly’s decision to offer Zepbound in a single-dose vial format for cash-paying patients is part of a broader effort to increase access to the weight loss drug. 

Advertisement

Next Up in Pharmacy

  • The number of active drug shortages has declined sharply since June, according to the FDA’s drug shortage database. Seventy-five drugs…

  • From payer shifts to regulatory milestones, GLP-1 therapies for obesity and diabetes continued to reshape the healthcare landscape in December.…

  • In 2025, the FDA approved 73 first-time generic drugs.  Here are the generics and their indication, in order of approval…

Advertisement